Mankind Pharma quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	4,338	3,697	+17.3%
EBITDA	1,171	921	+27.1%
EBITDA margin	27.0%	24.9%	+2.1 pts
Profit before tax	925	622	+48.9%
Net profit	716	520	+37.7%
EPS	₹17.23	₹12.39	+39.1%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	4,338	4,031	3,443	3,567	3,697	3,570	3,079	3,230	3,077	2,893	2,441	2,607	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	94.9	45.0	114	72.8	91.9	79.9	251	77.3	109	101	92.1	70.1
	4,433	4,076	3,557	3,640	3,789	3,650	3,331	3,307	3,186	2,994	2,533	2,677
	675	685	555	553	594	586	554	536	462	473	436	457
	548	547	498	412	413	405	411	387	424	433	342	353
	−18.3	−134	−94.9	13.3	54.8	62.9	−90.0	11.8	−11.4	−93.4	−41.3	18.1
	949	914	752	824	825	783	716	710	646	634	582	568
	105	110	142	157	170	171	191	221	7.1	10.9	9.4	9.2
	236	226	223	223	222	219	231	192	106	108	105	110
	1,013	963	803	846	888	887	805	755	705	765	531	605
	3,507	3,310	2,878	3,028	3,167	3,113	2,818	2,813	2,339	2,330	1,964	2,119
	1,171	1,056	930	919	921	847	683	830	850	682	591	607
	936	830	707	697	700	628	452	638	744	574	486	497
Profit
	925	766	679	612	622	537	513	494	847	664	569	558
	0.0	0.0	−23.2	−107	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	925	766	656	506	622	537	513	494	847	664	569	558
	182	211	193	154	125	111	132	158	168	139	115	71.2
	31.1	−15.3	−93.1	−58.8	−21.4	−15.1	−45.1	−45.0	22.3	−14.2	−19.5	31.3
	213	195	99.8	95.1	104	95.9	86.4	113	190	125	95.0	103
	3.7	3.9	3.0	3.2	2.3	3.2	2.3	3.4	2.6	3.9	2.4	4.6
	716	574	559	414	520	445	425	385	659	543	477	460
	712	570	556	411	518	441	427	381	656	539	474	455
	0.0	0.0	0.0	0.0	0.0	0.0	−4.3	0.0	0.0	0.0	0.0	0.0
	−0.9	−20.3	28.9	6.0	22.9	−0.8	−13.9	10.9	−2.2	−3.1	−8.4	5.8
	715	554	588	420	543	444	411	395	657	540	468	466
	711	—	554	409	512	438	425	380	653	536	471	454
	4.6	—	5.1	5.1	8.7	6.3	3.9	4.3	5.4	6.6	5.4	6.1
Per share
	₹17.23	₹13.76	₹13.44	₹9.90	₹12.39	₹10.62	₹10.19	₹9.45	₹16.31	₹13.39	₹11.76	₹11.33
	₹17.20	₹13.74	₹13.41	₹9.89	₹12.38	₹10.60	₹10.18	₹9.44	₹16.28	₹13.37	₹11.74	₹11.31
Continuing & discontinued operations
	0.0	0.0	0.0	0.0	0.0	0.0	−4.9	0.0	0.0	0.0	0.0	0.0
	0.0	0.0	0.0	0.0	0.0	0.0	−0.6	0.0	0.0	0.0	0.0	0.0
Other comprehensive income — detail
	−0.9	−20.3	28.9	6.0	22.9	−0.8	−13.9	—	—	—	—	—
	8.0	−8.2	15.5	2.3	21.6	−7.5	−10.3	9.0	−2.3	−1.9	−9.5	8.9
	1.8	−2.1	3.5	−0.5	4.7	−1.5	−2.2	—	—	—	—	—
	—	—	—	—	—	—	—	1.0	−1.5	−0.7	−2.2	1.8
	−7.0	−14.2	16.9	3.2	6.0	5.2	−5.8	2.9	−1.4	−1.9	−1.0	−1.4
	711	—	583	415	534	438	407	391	652	533	463	459
	4.6	—	5.5	5.1	8.8	6.3	4.1	4.2	5.1	6.6	5.4	6.1
Per share — as-filed variants
	₹17.23	₹13.76	₹13.44	₹9.90	₹12.39	₹10.62	₹10.30	₹9.45	₹16.31	₹13.39	₹11.76	₹11.33
	₹17.20	₹13.74	₹13.41	₹9.89	₹12.38	₹10.60	₹10.29	₹9.44	₹16.28	₹13.37	₹11.74	₹11.31
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	−₹0.11	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	−₹0.11	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	3,134	2,932	2,485	2,589	2,635	2,517	2,204	2,295	2,202	2,081	1,704	1,779
	72.2%	72.8%	72.2%	72.6%	71.3%	70.5%	71.6%	71.0%	71.6%	71.9%	69.8%	68.3%
Adjusted (ex-exceptional items) — derived
	925	766	679	612	622	537	513	494	847	664	569	558
	0.0	0.0	−23.2	−107	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	716	574	579	500	520	445	425	385	659	543	477	460
	₹17.23	₹13.76	₹13.91	₹11.97	₹12.39	₹10.62	₹10.19	₹9.45	₹16.31	₹13.39	₹11.76	₹11.33

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MANKIND₹2,490.00

Mankind Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSUNPHARMA CIPLA TORNTPHARM LAURUSLABS BIOCON ALKEM LUPIN GLENMARKMcap ₹1.03L Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	2,607.0	2,441.1	2,893.4	3,076.5	3,230.0	3,079.4	3,570.4	3,697.2	3,567.2	3,442.9	4,030.6	4,337.9
Other Income	70.1	92.1	100.6	109.4	77.3	251.3	79.9	91.9	72.8	114.3	45.0	94.9
Total Income	2,677.1	2,533.2	2,994.0	3,185.9	3,307.3	3,330.7	3,650.2	3,789.0	3,640.0	3,557.2	4,075.6	4,432.7
Expenses
+ Cost of Materials Consumed	456.7	436.3	473.0	462.0	536.1	554.3	585.7	594.4	553.0	555.0	684.9	674.8
+ Purchases of Stock-in-Trade	352.8	342.3	433.0	424.3	387.3	411.1	405.0	413.0	411.7	498.4	547.3	547.7
+ Changes in Inventories	18.1	-41.3	-93.4	-11.4	11.8	-90.0	62.9	54.8	13.3	-94.9	-133.9	-18.3
+ Employee Benefit Expense	568.4	581.5	633.8	646.4	709.7	715.8	783.4	825.2	823.7	751.6	913.5	948.9
+ Finance Costs	9.2	9.4	10.9	7.1	220.9	190.5	170.7	169.7	157.2	141.8	110.0	104.9
+ Depreciation & Amortisation	109.7	104.7	107.7	105.6	192.3	230.9	218.7	221.8	222.6	223.1	225.7	235.7
+ Other Expenses	604.5	531.2	765.4	705.2	755.3	805.0	886.6	888.5	846.1	803.1	962.6	1,013.5
Total Expenses	2,119.4	1,964.1	2,330.3	2,339.2	2,813.4	2,817.6	3,112.9	3,167.3	3,027.6	2,877.9	3,310.1	3,507.3
EBITDA	606.5	591.1	681.8	850.0	829.8	683.2	846.8	921.3	919.4	929.9	1,056.2	1,171.3
EBIT	496.8	486.4	574.0	744.4	637.5	452.3	628.1	699.5	696.8	706.8	830.5	935.5
Profit
PBT before Exceptional Items	557.7	569.2	663.7	846.8	493.9	513.1	537.3	621.7	612.4	679.3	765.5	925.4
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-106.6	-23.2	0.0	0.0
Pretax Income	557.7	569.2	663.7	846.8	493.9	513.1	537.3	621.7	505.8	656.2	765.5	925.4
+ Current Tax	71.2	114.5	138.7	168.1	157.8	131.5	110.9	125.2	153.9	192.9	210.6	181.9
+ Deferred Tax	31.3	-19.5	-14.2	22.3	-45.0	-45.1	-15.1	-21.4	-58.8	-93.1	-15.3	31.1
Tax Expense	102.5	95.0	124.6	190.4	112.8	86.4	95.9	103.8	95.1	99.8	195.4	213.0
+ Share of Associates & JVs	4.6	2.4	3.9	2.6	3.4	2.3	3.2	2.3	3.2	3.0	3.9	3.7
Net Income	459.8	476.6	543.1	658.9	384.5	424.7	444.6	520.2	413.9	559.4	574.1	716.1
+ Net Income — Continuing Ops	455.2	474.2	539.2	656.3	381.1	426.7	441.5	517.9	410.7	556.4	570.2	712.4
+ Net Income — Discontinued Ops	0.0	0.0	0.0	0.0	0.0	-4.3	0.0	0.0	0.0	0.0	0.0	0.0
+ Other Comprehensive Income	5.8	-8.4	-3.1	-2.2	10.9	-13.9	-0.8	22.9	6.0	28.9	-20.3	-0.9
Total Comprehensive Income	465.6	468.2	540.0	656.7	395.5	410.7	443.9	543.1	419.8	588.4	553.8	715.3
Net Income to Common	453.8	471.2	536.5	653.5	380.2	425.1	438.3	511.5	408.8	554.4	—	711.5
Minority Interest	6.1	5.4	6.6	5.4	4.3	3.9	6.3	8.7	5.1	5.1	—	4.6
Per Share
Basic EPS	11.33	11.76	13.39	16.31	9.45	10.19	10.62	12.39	9.90	13.44	13.76	17.23
Diluted EPS	11.31	11.74	13.37	16.28	9.44	10.18	10.60	12.38	9.89	13.41	13.74	17.20
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	0.0	0.0	0.0	0.0	0.0	-4.9	0.0	0.0	0.0	0.0	0.0	0.0
+ Tax — Discontinued Operations	0.0	0.0	0.0	0.0	0.0	-0.6	0.0	0.0	0.0	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-13.9	-0.8	22.9	6.0	28.9	-20.3	-0.9
+ Items NOT to be Reclassified to P&L	8.9	-9.5	-1.9	-2.3	9.0	-10.3	-7.5	21.6	2.3	15.5	-8.2	8.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-2.2	-1.5	4.7	-0.5	3.5	-2.1	1.8
+ Tax on Items NOT to be Reclassified — alt tag	1.8	-2.2	-0.7	-1.5	1.0	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-1.4	-1.0	-1.9	-1.4	2.9	-5.8	5.2	6.0	3.2	16.9	-14.2	-7.0
Comprehensive Income — Owners of Parent	459.5	462.8	533.3	651.6	391.3	406.6	437.6	534.3	414.8	582.9	—	710.7
Comprehensive Income — Non-controlling Interests	6.1	5.4	6.6	5.1	4.2	4.1	6.3	8.8	5.1	5.5	—	4.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	11.33	11.76	13.39	16.31	9.45	10.30	10.62	12.39	9.90	13.44	13.76	17.23
Diluted EPS — Continuing Operations	11.31	11.74	13.37	16.28	9.44	10.29	10.60	12.38	9.89	13.41	13.74	17.20
Basic EPS — Discontinued Operations	0.00	0.00	0.00	0.00	0.00	-0.11	0.00	0.00	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	0.00	0.00	0.00	0.00	0.00	-0.11	0.00	0.00	0.00	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,779.4	1,703.8	2,080.9	2,201.6	2,294.8	2,204.0	2,516.8	2,635.0	2,589.2	2,484.6	2,932.3	3,133.6
Gross Margin %	68.25	69.80	71.92	71.56	71.05	71.57	70.49	71.27	72.58	72.16	72.75	72.24
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	557.7	569.2	663.7	846.8	493.9	513.1	537.3	621.7	612.4	679.3	765.5	925.4
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-106.6	-23.2	0.0	0.0
Net Income Adj (tax-effected)	459.8	476.6	543.1	658.9	384.5	424.7	444.6	520.2	500.4	579.1	574.1	716.1
EPS Adj	11.33	11.76	13.39	16.31	9.45	10.19	10.62	12.39	11.97	13.91	13.76	17.23
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Filed Debt Equity	—	—	—	—	—	0.59	—	—	—	0.39	0.25	—
Filed Dscr	—	—	—	—	—	0.13	—	—	—	0.17	0.59	—
Filed Iscr	—	—	—	—	—	2.39	—	—	—	4.84	8.61	—
Paid Up Equity Capital	40.1	40.1	40.1	40.1	41.3	41.3	41.3	41.3	41.3	41.3	41.3	41.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Mankind Pharma Q2 FY27 results (July–September 2026)

Filed with NSE on Monday, 26 October 2026 at 3:07 pm IST

Mankind Pharma (NSE: MANKIND) reported its Q2 FY27 results (July–September 2026) on Monday, 26 October 2026 at 3:07 pm IST. Consolidated net profit attributable to shareholders was ₹711 crore, up 39.1% from ₹512 crore in Q2 FY26 and up 23.9% from ₹574 crore in Q1 FY27. Revenue from operations was ₹4,338 crore, up 17.3% year on year and up 7.6% from the previous quarter.

Q2 FY26 results (a year earlier): 6 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit (shareholders'): ₹711 Cr+39.1% vs Q2 FY26+23.9% vs Q1 FY27Total incl. minority interest ₹716 Cr
Revenue from operations: ₹4,338 Cr+17.3% vs Q2 FY26+7.6% vs Q1 FY27
Operating margin (EBIT): 21.6%+2.6 pts vs Q2 FY26+1.0 pts vs Q1 FY27EBIT ₹936 Cr
EBITDA: ₹1,171 Cr+27.1% vs Q2 FY26+10.9% vs Q1 FY27margin 27.0%
Earnings per share (basic): ₹17.23+39.1% vs Q2 FY26+25.2% vs Q1 FY27
Net profit margin: 16.4%+2.6 pts vs Q2 FY26+2.2 pts vs Q1 FY27

Questions

What was Mankind Pharma's net profit in Q2 FY27?

Consolidated net profit attributable to shareholders was ₹711 crore, up 39.1% from ₹512 crore in Q2 FY26 and up 23.9% from ₹574 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹716 crore.

How were Mankind Pharma's Q2 FY27 results?

Both grew from a year earlier: net profit was up 39.1% at ₹711 crore and revenue was up 17.3% at ₹4,338 crore. The operating margin was 21.6%, up 2.6 percentage points from 18.9% a year earlier. Against Q1 FY27, net profit was up 23.9% and revenue up 7.6%.

What is Mankind Pharma's net profit margin?

Mankind Pharma's net profit margin was 16.4% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations), against 13.8% in Q2 FY26 (up 2.6 percentage points). For FY26 as a whole it was 13.4%.

What was Mankind Pharma's revenue in Q2 FY27?

Revenue from operations was ₹4,338 crore, up 17.3% year on year and up 7.6% from the previous quarter.

What was Mankind Pharma's EPS in Q2 FY27?

Basic earnings per share were ₹17.23, against ₹12.39 in Q2 FY26.

What was Mankind Pharma's revenue in FY26?

Revenue from operations was ₹14,278 crore in FY26 (April 2025–March 2026), up 17.0% from ₹12,207 crore in FY25. It was ₹10,335 crore in FY24 and ₹8,749 crore in FY23: up 63.2% over three years, 17.7% a year on average.

What was Mankind Pharma's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹936 crore, a margin of 21.6%, against 20.6% in Q1 FY27 and 18.9% in Q2 FY26. EBITDA was ₹1,171 crore, 27.0% of revenue.

What was Mankind Pharma's net profit in the first half of FY27?

Consolidated net profit attributable to shareholders for the first half of FY27 (April–September 2026) was ₹1,286 crore, up 35.3% from ₹950 crore in the same months a year earlier. Revenue from operations was ₹8,368 crore, up 15.1%.

What was Mankind Pharma's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹1,913 crore in FY26 (April 2025–March 2026), down 3.7% from ₹1,986 crore in FY25. It was ₹1,913 crore in FY24 and ₹1,282 crore in FY23: up 49.2% over three years, 14.3% a year on average.

How has Mankind Pharma's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹409 crore in Q3 FY26, ₹554 crore in Q4 FY26, ₹574 crore in Q1 FY27 and ₹711 crore in Q2 FY27. That is ₹2,249 crore over the four quarters, up 28.1% from ₹1,755 crore in the four quarters before. Revenue from operations: ₹3,567 crore, ₹3,443 crore, ₹4,031 crore and ₹4,338 crore.

When did Mankind Pharma announce its Q2 FY27 results?

On Monday, 26 October 2026 at 3:07 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 6 November 2025.

When will Mankind Pharma announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Mankind Pharma figures come from?

From Mankind Pharma's own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 26 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.